Clarus Therapeutics Holdings Inc (CRXTQ)

[Hercules1]

CRXT:


no doubt.

this is one of the more undervalued biotechs.

they are on the cutting edge of this absolutely vital drug.


Clarus Therapeutics (NASDAQ: CRXT) CEO Dr. Robert Dudley: "Advancing Androgen and Metabolic Therapies"

Clarus Therapeutics (NASDAQ: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, announced the initiation of screening for the first patient in an investigator-initiated Phase 4 clinical trial designed to evaluate the efficacy and safety of JATENZO (testosterone undecanoate) oral softgel capsules for the treatment of adult hypogonadal men with chronic kidney disease (CKD). Clarus expects to announce results from the trial in the first half of 2023.

CEO Dr. Robert Dudley commented, "We are excited screening has begun for the first patient in this trial of hypogonadal men with CKD. Patients with CKD suffer from a myriad of comorbidities, which often include profound reductions in circulating T. Epidemiological data indicate that an estimated two million men with CKD are clinically hypogonadal and thus may benefit from T replacement therapy. This will be the first of several life cycle management studies for JATENZO designed to maximize the potential for treatment of specific patient populations where T deficiency is a component of their compromised health. Because JATENZO increases T levels and has a positive impact on hemoglobin levels, our hypothesis is that JATENZO, with its flexible oral dosing options, could become an important treatment option for hypogonadal adult men with CKD. These men also may prefer JATENZO over other T treatment modalities because it is administered orally as a softgel capsule."

Clarus Therapeutics (NASDAQ: CRXT) News: https://www.wallstreetreporter.com/2022/03/16/clarus-nasdaq-crxt-announces-initiation-of-phase-4-clinical-trial/

WALL STREET REPORTER